From: Tuberculosis screening costs and cost-effectiveness in high-risk groups: a systematic review
Study, year | Type of economic evaluation | Empirical study or modelling | Time horizon | Source of costing | Primary outcome | Sensitivity analysis | Key scenarios | WTP threshold |
---|---|---|---|---|---|---|---|---|
Abimbola et al. 2012 | Decision analytic model | Modelling | 6 months after ART initiation | South Africa specific published literature | ICER ($/TB death averted) | One-way and probabilistic | Mortality rates, cost inputs | Per-capita South African 2012 GDP ($5,678 USD) |
Adelman et al. 2017 | Decision analytic model | Modelling | 10 years | Parent study results, AHRI HIV clinic, published literature | ICER ($/DALY averted) | One-way | Varied model inputs based on ranges in the literature | Per-capita Ethiopian 2014 GDP ($505 USD) |
Andrews et al. 2012 | Decision analytic model | Modelling | Lifetime | Cape Town AIDS Cohort, unit costs from hospitals, published literature from South Africa | ICER ($/YLS) | One-way and two-way | Varied key parameters and costs | Per-capita South African 2010 GDP ($7,100 USD) |
Bassett et al. 2010 | Cost analysis | Empirical | N/A | HIV clinic data (McCord hospital) | Cost ($/TB case identified) | N/A | Subset of patients with cough at study entry | N/A |
Bogdanova et al. 2019 | Cost analysis | Empirical | N/A | Finance department, medical insurance fund | Cost ($/TB case detected) | N/A | N/A | N/A |
James et al. 2017 | Cost analysis | Empirical | N/A | CENAT, National TB and Leprosy program, TB REACH | Cost ($/TB case detected) | N/A | N/A | N/A |
Ji et al. 2020 | Cost-effectiveness analysis; cost-utility and cost benefit analyses | Modelling | 3 years | National Essential Public Health Program (NEPHS) | ICER ($/DALY gained) | One-way | Varied key parameters, and ROC curve | 3 times per capita 2016 GDP ($ CNY not stated) |
Jit et al. 2011 | Decision analytic model | Modelling | N/A | Find and Treat program records, NICE guidelines | ICER ($/QALY gained) | One-way | Varied all key parameters | 20–30,000 GBP per QALY |
Jo et al. 2020 | Cost analysis | Empirical | 2 years | TB REACH budgets and financial reports, program data | Cost ($/TB case identified) | N/A | N/A | N/A |
Karki et al. 2017 | Cost analysis | Empirical | N/A | Program expenditures and budget | Cost ($/TB case detected) | N/A | N/A | N/A |
Kranzer et al. 2012 | Cost analysis | Empirical | 20 months | Study data and published literature | Cost ($/TB case detected) | One-way | Varied staff salaries and discount rates | N/A |
Machekera et al. 2019 | Cost analysis | Empirical | N/A | ZimACF project data | Cost ($/case diagnosed) | One-way | Varied all unit costs | N/A |
Maheswaran et al. 2012 | Cost-effectiveness analysis | Modelling | 2 years | Published data | ICER ($/QALY) | Probabilistic | VOI used as alternative to univariate SA | Per capita 2010 SSA GNI ($2167 USD) |
Murray et al. 2016 | Decision analytic model | Modelling | Lifetime | Published literature | ICER ($/life year gained) | One-way, multi-way, and probabilistic | Per capita 2014 Ugandan GNI ($680 USD) | |
Orlando et al. 2018 | Cost-effectiveness analysis | Modelling | 1 year | DREAM program, Global Fund data, published literature | ICER ($/DALY averted) | One-way | Varied all key parameters | Per capita 2016 Mozambique GDP ($382 USD) |
Reddy et al. 2019 | Cost-effectiveness analysis | Modelling | 2 and 5 years, lifetime | STAMP trial, published literature | ICER ($/Year of life saved (YLS)) | One-way, multi-way | Varied all key parameters | Malawi ($750 USD); South Africa ($940 USD) |
Sekandi et al. 2015 | Cost-effectiveness analysis | Modelling | 1.5 years | Uganda NTP, program data and published literature | ICER ($/additional TB case detected) | One-way | Varied costs and probabilities | Twice per capita 2013 Ugandan GDP ($1102 USD) |
Shah et al. 2017 | Cost-effectiveness analysis | Modelling | N/A | Peru NTP data, published literature | ICER ($/DALY averted) | One-way | Varied all model parameters | Per capita 2014 Peruvian GNI ($6300 USD) |
Shah et al. 2009 | Cost analysis | Empirical | N/A | Program data | Cost ($/TB case diagnosed) | N/A | N/A | N/A |
Shah et al. 2008 | Cost analysis | Empirical | N/A | Provincial TB and HIV/AIDS program data | Cost ($/TB case diagnosed) | N/A | N/A | N/A |
Smit et al. 2017 | Cost-effectiveness analysis | Empirical | 1 year | Flemish Association for Respiratory Health and TB Control | ICER (Euros/TB case detected) | One-way | Varied costs and number of cases detected | N/A |
Sohn et al. 2019 | Cost analysis | Empirical | 1 year | Asha Kalp program finance and operations data | Cost ($/TB case detected) | One-way | Top-down and bottom-up cost estimates provided | N/A |
Winestsky et al. 2012 | Decision analytic model | Modelling | 10 years | Primary data in prisons, published literature from Russia, Tajikistan and Latvia | ICER ($/QALY gained) | One-way, selected two-way, situational analyses | Varied all key parameters, and plausible situational analyses | Varied WTP thresholds |
Yoon et al. 2019 | Cost analysis | Empirical | N/A | Program data | Cost ($/TB case diagnosed) | N/A | N/A | N/A |
Zhang et al. 2016 | Cost analysis | Empirical | N/A | Program data | Cost ($/TB case diagnosed) | N/A | N/A | N/A |
Zishiri et al. 2014 | Cost analysis | Empirical | N/A | Department of Correctional Services finance data, published literature | Cost ($/TB case identified) | One-way | Changed base-case parameters | N/A |
Zwerling et al. 2015 | Decision analytic model | Modelling | Lifetime (assumed 59.2 years) | Cost and operational analysis of four study sites, published literature | ICER ($/DALY averted) | One-way, two-way and probabilistic uncertainty analysis | Varied all key parameters | Per capita 2010 average SSA GDP ($1417 USD) |